Why Did NEUP Stock Surge 64% Today?

• Lynx1 Capital Management LP boosted its stake in Neuphoria Therapeutics by acquiring 639,110 shares.
• The shares were bought at prices ranging from $4.96 to $5.20, with an average cost of $5.137 per share.
• On Monday, Nuphoria announced a comprehensive strategic review of its business operations and pipeline.

Neuphoria Therapeutics Inc. (NEUP) stock drew heightened attention from retail investors after prominent investor Lynx1 Capital Management LP increased its stake by acquiring 639,110 shares.

The share purchase, made on October 21, was disclosed in a Securities and Exchange Commission (SEC) filing. 

Pricing Details 

The shares were bought at prices ranging from $4.96 to $5.20, with an average cost of $5.137 per share. In total, Lynx1 Capital spent $3.3 million to expand its position. 

Following this acquisition, the investment firm now controls 875,328 shares of Neuphoria Therapeutics. The transaction highlights growing investor confidence in Neuphoria’s pipeline and market potential.

Neuphoria Therapeutics’ stock traded over 64% higher on Friday morning and was the second-most trending equity ticker on Stocktwits. Retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.

Neuphoria focuses on creating treatments for neuropsychiatric conditions. Its main drug candidate, BNC210, is an anti-anxiety therapy designed to rebalance brain neurotransmitters and deliver fast relief from anxiety and stress without causing sedation, cognitive issues, or dependency.

AFFIRM-1 Phase 3 Trial Update 

On Monday, Neuphoria said its late-stage clinical trial for the drug BNC210 did not meet the main or secondary goals in treating patients with social anxiety disorder (SAD). The company announced the findings from its Phase 3 AFFIRM-1 study, which measured changes in anxiety levels using the Subjective Units of Distress Scale (SUDS) during a public speaking challenge.

However, building on earlier positive data from studies involving chronic daily dosing, Neuphoria said it will assess new development paths for BNC210 as a treatment for post-traumatic stress disorder (PTSD). 

The company had also announced a comprehensive strategic review of its business operations and pipeline, with an update expected by the end of 2025.

Neuphoria stock has gained over 78% in 2025 and over 41% in the last 12 months. 

Also See: Why Did NEUP Stock Surge 64% Today?

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on